⌕
Takeda Pharmaceutical · TAK · NYSE
Tenet 32 · Weak
Compare
$21.59+0.75%At closeTenet 32 · Weak
$21.59+0.16 (+0.75%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD

Takeda Pharmaceutical (TAK) Earnings Forecast

What Wall Street expects this business to earn, and how much analysts disagree.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

9 figures withheld by our checks. Each blank figure names its reason.

Estimates are in the company's reporting currency and are not compared to the USD share price on this page. Filed figures are in US dollars. Nothing here converts between the two.
Consensus as of Nov 13, 2026 · we check it nightly

Analysts expect Takeda Pharmaceutical to earn 67.24 a share in FY27 and 168.28 in FY31, growing about 26% a year. 3 analysts publish an estimate for FY27 and 1 for FY31.

Forward P/E · FY27E
Not shown
the estimate and the price are in different currencies
FY27 EPS revisions · 30 days
▲ +8.7%
61.87 to 67.24, one fiscal year at both ends
Disagreement · FY27
100.8%
high to low, 17.21 to 84.99
Coverage · FY27
3 · 9
EPS estimates · revenue estimates
Work out what the consensus implies at a multiple you chooseConsensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Are estimates going up or down lately?

The FY27 EPS consensus is 67.24, up 8.8% in 91 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 91 days. One step per nightly change.

−8.5%+11.8%+32.1%FY27 +8.8%FY28 +5.1%Aug 15Nov 13
EPS30 days90 daysshown aboveSince Jul 9
FY273 analysts▲ +8.7%61.87 to 67.24▲ +8.8%61.80 to 67.24▲ +13.0%59.53 to 67.24
FY282 analysts▲ +6.6%99.05 to 105.62▲ +5.1%100.46 to 105.62▲ +7.1%98.61 to 105.62
Sep '261 analyst▼ −1.8%23.35 to 22.92▼ −1.4%23.25 to 22.92▼ −1.3%23.21 to 22.92
Dec '261 analyst▼ −6.0%23.98 to 22.55▼ −13.1%25.95 to 22.55▼ −13.1%25.95 to 22.55

Contributors at both ends of the window: FY27 2 and 3. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 13, 2026 · consensus as of Nov 13, 2026

The FY28 consensus is 105.62 a share in the company's reporting currency, and a ratio carries no currency, so a multiple can still be chosen. We stop before the product: it would be a price in the reporting currency, and this share trades in US dollars.

Consensus EPS · FY28
105.62
2 analysts · low 93.59, high 113.64 · thin coverage
Multiple · five-year average P/E
37.3×
Average of the fiscal-year P/Es, FY21 to FY25. A ratio carries no currency.
×
Receipt · TAK · FY28Nov 13, 2026
Implied, a share
Not computed

We do not convert currencies here. The estimate is in the reporting currency and the share trades in US dollars, so the product would be a price in neither.

Drag the multipleShaded: where Takeda Pharmaceutical's P/E sat at each fiscal year end, FY19 to FY25. Each dot is one year.
20×30×40×50×60×
5-yr avg 37.3×10-yr median 49.3×

Each point on the line is a multiple, and the flag is the price it implies for FY28. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Not computed across currencies. The consensus is in Takeda Pharmaceutical's reporting currency and the share trades in US dollars, so there is no multiple of this year's estimate to set against a growth rate.Show the multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY19 to FY25 · over 7 fiscal years. The mark is the median of the last 7.
18.5× low114.6× high
49.3× median
We hold no trailing multiple for this company today, so nothing marks today on the track. A ratio carries no currency, so the record itself is unaffected.

How much do analysts disagree?

For FY31, estimates run from 162.69 to 174.95 around an average of 168.28, drawn by 1 analyst.

FY27E3 analysts
17.21 to 84.99 · 100.8%
FY28E2 analysts
93.59 to 113.64 · 19.0%
FY29E1 analyst
123.64 to 132.96 · 7.3%
FY30E1 analyst
180.23 to 193.82 · 7.3%
FY31E1 analyst
162.69 to 174.95 · 7.3%

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. The last filed figure is in US dollars, so it is not placed on this axis.

Is next quarter a high bar or an easy one?

Analysts expect Takeda Pharmaceutical to earn 22.55 a share in the December quarter, the one estimate published. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
1,187.2B
3 analysts, 1,181.0 to 1,193.4 in reporting ccy B

For the March quarter, analysts expect a loss of 28.94 a share.

Does Takeda Pharmaceutical usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Takeda Pharmaceutical begins on Jul 9, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.

We started recording estimates on Jul 9, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Jun '29
Sep '29
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Takeda Pharmaceutical on Jul 9, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow 2.2% in FY28 and EPS 57.1%. Little of it is sales: the net margin moves from 4.6% to 7.0%, and the implied share count from about 3.21B to 3.21B, so these numbers assume the count stands still.Show the decomposition and the margin ladderHide the decomposition
FY28 EPS growth, in points
Revenue growth+2.2
Net margin change+54.9
Share count change0.0
EPS growth+57.1
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
3 analysts publish an EPS estimate for FY27 and 9 publish revenue. Coverage thins with distance: 1 EPS estimate for FY31. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
93
FY27E
82
FY28E
41
FY29E
41
FY30E
31
FY31E
The FY27 panel held 1 analyst when our record of it began on Jul 9, 2026 and holds 3 tonight.

The full consensus, year by year

Consensus as of Nov 13, 2026 · filed figures as reported
Revenue · reporting ccy Bfiled · consensus average · band = low to high
−2972,6855,666historyStreet forecastFY23FY26FY31E

Coverage thins with distance: 9 revenue estimates for FY27, 3 for FY31.

Diluted EPS · reporting ccyfiled · consensus average · band = low to high
−12.2794.66201.60historyStreet forecastFY23FY26FY31E

Out-year bands widen as fewer analysts publish: 3 EPS estimates for FY27, 1 for FY31.

Fiscal yearRevenue reporting ccy BYoYEPS reporting ccyYoYEBITDA reporting ccy BNet inc. reporting ccy BShares BAnalysts rev · EPSFwd P/E
FY26Filed · USD28.3—−0.61————as filedn/m
FY27E4,719.04,688.9 to 4,747.5n/ca67.2417.21 to 84.99n/ca1,114.5215.53.219 · 3—
FY28E4,822.94,697.0 to 4,950.5▲2.2%105.6293.59 to 113.64▲57.1%1,230.8338.63.218 · 2—
FY29E4,986.24,858.7 to 5,138.3n/cb127.89123.64 to 132.96n/cb1,292.9410.03.214 · 1—
FY30E5,288.45,153.1 to 5,449.6▲6.1%186.43180.23 to 193.82▲45.8%1,513.4597.63.214 · 1—
FY31E5,184.75,052.1 to 5,342.8▼2.0%168.28162.69 to 174.95▼9.7%1,424.7539.43.213 · 1—

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 3 EPS estimates for FY27, 9 for revenue. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.